口服的乌尔索多西胆酸与AMD的发病率降低有关
Kevin R Zhang1, Rohini M Nair1, Yineng Chen2
1F.M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Clinical therapeutics
|September 9, 2025
概括
在患有胆囊疾病的患者中,乌尔索多胆酸 (UDCA) 显著降低了35%的与年龄相关的黄斑变性 (AMD) 风险. 这一发现表明UDCA可能是AMD预防的潜在治疗剂.
科学领域:
- 眼科医生 眼科 眼科
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 胆结石 (胆结石) 与与年龄相关的黄斑变性 (AMD) 的风险降低有关.
- 在临床前模型中,用于胆结石溶解的胆汁酸乌尔索西胆酸 (UDCA) 显示出视网膜保护性质.
- 关于UDCA预防AMD的潜力,需要进行调查.
研究的目的:
- 调查UDCA使用与患有胆囊疾病的患者患AMD的风险之间的关联.
- 评估UDCA是否对AMD进展产生保护作用.
主要方法:
- 一项回顾性队列研究分析了2000-2022年的数据.
- 患有胆囊疾病 (胆病,胆囊炎或胆囊切除术) 的患者被分为UDCA使用者和非使用者 (对照组).
- 倾向性得分匹配和考克斯回归与治疗权重的逆概率 (IPTW) 用于控制混因素.
主要成果:
- 该研究包括5,863名UDCA用户和17,164名匹配对照,所有55岁以上,没有先前的AMD病史.
- 使用UDCA与AMD发病率显著降低相关 (6.74%与9.00%).
- 调整后的危险比率为0.65 (95% CI:0.58-0.74,P < 0.0001),表明使用UDCA时AMD危险降低了35%.
结论:
- 在患有胆囊疾病的人群中,UDCA与AMD风险的大幅降低有关.
- 建议进一步研究UDCA的保护作用背后的机制性途径.
- 需要进行临床试验,评估UDCA对AMD的预防或治疗.
相关概念视频
01:27Open Angle Glaucoma: Treatment
963
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
963
01:28Angle Closure Glaucoma: Treatment
1.2K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.2K
01:26Atherosclerosis III: Management
322
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
322
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
229
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
229
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
947
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
947